Myriad Genetics, Inc.

590 articles with Myriad Genetics, Inc.

• Thomas P. Slavin, M.D., Named Chief Medical Officer for Myriad Genetics

  6/16/2021

  SALT LAKE CITY, June 16, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has named Thomas P. Slavin Jr. (T.J.), M.D., FACMG, DABMD, chief medical officer of the company. He will report directly to Nicole Lambert, president of Myriad Genetic Laboratories. In his new role, Dr. Slavin will apply deep clinical and scientific expertise, combined with proven leadership and experience in precision medicine, t

• Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference

  6/4/2021

  Paul J. Diaz, president and CEO of Myriad Genetics, a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Goldman Sachs 2021 Virtual Global Healthcare Conference at 8:50 a.m. EST on June 10, 2021.

• Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

  6/1/2021

  On May 28, 2021, Myriad Genetics, Inc., a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash.

• IPM Launches GeneSight® Pharmacogenomics Program for Depression and Anxiety

  5/27/2021

  Integrated Prescription Management, a leading pharmacy benefits management company, now offers pharmacogenomics testing for patients suffering from depression or anxiety.

• Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

  5/24/2021

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced it has signed a definitive agreement to sell Myriad RBM, Inc.

• Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health BusinessNew President Brings Proven Track Record in Women’s Health; Direct to Physician and Direct to Patient Commercial Expertise

  5/20/2021

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Melissa Gonzales has been named president of its Women’s Health business.

• Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

  5/19/2021

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will present results from a study with more than 275,000 women validating the use of a new method for polygenic breast cancer risk assessments in women of all ancestries. The new data will be shared in an oral presentation with leading collaborators on June 4 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference

  5/5/2021

  Paul J. Diaz, president and CEO of Myriad Genetics, Inc., a leader in genetic testing and precision medicine, will discuss the company’s transformation plan and growth initiatives during a fireside chat at the Bank of America Securities 2021 Virtual Health Care Conference at 2:45 p.m. EDT on May 12, 2021.

• Labcorp to Acquire Myriad Autoimmune’s Vectra Testing Business From Myriad Genetics

  5/3/2021

  Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay. More than one million Vectra tests have been comp

• Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day

  5/3/2021

  Company continues to focus on expanding its reach and organic growth, expense control, and laying foundation for advancing leadership position in genetic testing and precision medicine

• Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp

  5/3/2021

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement to sell select operating assets and intellectual property, including the Vectra® test, from Myriad Autoimmune’s business unit to Labcorp for $150 million in cash.

• Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and TreatmentNew poll shows 83% of people with depression agree life would be easier if others could understand their depression

  4/28/2021

  In a new nationwide poll, the GeneSight® Mental Health Monitor found that 83% of people with depression agree that life would be easier if others could understand their depression.

• 

  Sun's Out to Play, But So Is Skin Cancer - Here's What Pharma is Doing About It

  4/27/2021

  There are several experimental treatments undergoing study for types of melanoma. BioSpace rounds up some of the most recent clinical news in this space.

• Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021

  4/27/2021

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that it will release its financial results for the quarter ended March 31, 2021 at 4:05 pm EDT on May 3, 2021.

• Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

  4/27/2021

  Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced that it has signed a definitive agreement to sell the Myriad myPath Melanoma, LLC, Laboratory, which is the laboratory that offers the myPath Melanoma test, to Castle Biosciences for $32.5 million in cash.

• Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders

  3/29/2021

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Eric Santa as its new Chief Growth Officer

• Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services

  3/2/2021

  Strategic collaboration combines germline genetic testing, next-generation tumor sequencing and world-class testing capabilities to elevate global precision oncology care

• Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan

  2/23/2021

  In the midst of the COVID-19 pandemic, we continued to support our patients and healthcare providers with critical genetic insights needed to drive better health outcomes.

• Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021

  2/16/2021

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will hold its quarterly earnings conference call for the period ending December 30, 2020 with investors and analysts at 4:30 p.m. EST on Tuesday, February 23, 2021.

• New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer

  2/12/2021

  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris ® test and its ability to help accurately predict which men with more aggressive prostate cancer will benefit from intensification of therapy and which patients may safely avoid such treatments.